Biotech Firm $ATXS Faces Shareholder Concerns Over Dilution Impact on Stock Price Despite Positive Clinical Data

DickMedChem@DickMedChem

2 years ago

Bought some $ATXS PM and sold it a few moments later with some gains. Better than nothing.

HAE not big movers on data anymore check $PHVS $KALV & now $ATXS

Sheep of Wall Street@Biohazard3737

2 years ago

$ATXS shows the impact of dilution on biotech total shareholder returns. As of June 30, 2021, the company had 18.2m shares outstanding and $140m in cash. The company has taken an mAB through P1b/2 since and - as expected - delivered strong clinical results. However, pre data…